Phaseline

Targets › GPRC3

GPRC3: drug programs, companies and trials

5 programs from 5 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on GPRC3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OriCell TherapeuticsOri-C101
GPC3-directed CAR-T cell therapy
GPRC3Phase 1Hepatocellular CarcinomaDec 2026
AstraZenecaAZD5851
GPC3-directed CAR-T cell therapy
GPRC3Phase 1Hepatocellular CarcinomaDec 2027
Peking UniversityOriC902
GPC3-targeted chimeric antigen receptor (CAR) T cell therapy
GPRC3Phase 1HCCDec 2027
Guangzhou FineImmune BiotechnologySuper CAR-T
GPC3-targeted CAR-T cell therapy
GPRC3Phase 1Advanced Hepatocellular Carcinoma (HCC)Apr 2028
Second Affiliated Hospital of Guangzhou Medical UniversityGPC3/Mesothelin-CAR-γδT cells
GPC3/Mesothelin-targeted CAR-γδT cell therapy
GPRC3, MSLNPhase 1Pancreas CancerNov 2030

Conditions

Hepatocellular Carcinoma (2) Pancreas Cancer (1) Advanced Hepatocellular Carcinoma (HCC) (1) HCC (1)

Modalities

other (2), protein or peptide (2), small molecule (1)

Companies

Second Affiliated Hospital of Guangzhou Medical University (1) AstraZeneca (1) OriCell Therapeutics (1) Guangzhou FineImmune Biotechnology (1) Peking University (1)

Related targets

MSLN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.